Graham Capital Management, L.P. Rigel Pharmaceuticals Inc Transaction History

Graham Capital Management, L.P.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$1.12 - $1.57 $2,991 - $4,193	-2,671 Reduced 6.8%	36,620 $54,000
Q4 2023 Feb 14, 2024	BUY	$0.72 - $1.56 $6,634 - $14,373	9,214 Added 30.63%	39,291 $56,000
Q3 2023 Nov 22, 2023	SELL	$1.07 - $1.39 $55,241 - $71,762	-51,628 Reduced 63.19%	30,077 $32,000
Q2 2023 Aug 14, 2023	BUY	$1.12 - $1.82 $78,844 - $128,122	70,397 Added 622.54%	81,705 $105,000
Q1 2023 May 15, 2023	BUY	$1.25 - $2.0 $14,135 - $22,616	11,308 New	11,308 $14,000
Q3 2022 Nov 14, 2022	BUY	$1.1 - $12.2 $895,006 - $9.93 Million	813,642 Added 668.83%	935,294 $1.1 Million
Q2 2022 Aug 15, 2022	SELL	$0.67 - $3.19 $109,348 - $520,627	-163,206 Reduced 57.29%	121,652 $137,000
Q1 2022 May 16, 2022	BUY	$2.22 - $3.45 $447,036 - $694,719	201,368 Added 241.19%	284,858 $851,000
Q4 2021 Feb 14, 2022	BUY	$2.36 - $3.57 $197,036 - $298,059	83,490 New	83,490 $221,000

334K

Ticker RIGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 172,836,000
Market Cap $2.96B
Description
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is ...

Get notified when there are updates to the investment portfolio of Graham Capital Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Graham Capital Management, L.P. with notifications on news.